Sen­ate Dems blast No­var­tis’ ties to Trump at­tor­ney, claim phar­ma gi­ant of­fered mis­lead­ing ex­pla­na­tions in damn­ing re­port

Sen­ate De­moc­rats is­sued a damn­ing re­port Fri­day morn­ing say­ing that their probe of the $1.2 mil­lion in pay­ments No­var­tis made to Don­ald Trump’s per­son­al at­tor­ney Michael Co­hen re­vealed that ex-CEO Joe Jimenez had ex­ten­sive con­tacts with Co­hen re­lat­ed to drug pol­i­cy and ac­cess to the White House, and that com­pa­ny of­fi­cials then went on to mis­lead the pub­lic re­cent­ly with their ex­pla­na­tion for what had hap­pened.

Joe Jimenez

The ex­plo­sive charges con­tend that rather than the brief and in­con­se­quen­tial con­tact No­var­tis claimed to have had with Co­hen, Jimenez was in con­tact with the at­tor­ney by phone on 4 oc­ca­sions, with mul­ti­ple email ex­changes over 6 months. The com­mu­ni­ca­tions in­clud­ed “the Trump ad­min­is­tra­tion’s drug pric­ing pro­pos­als, No­var­tis’s po­ten­tial in­vest­ment in a small drug com­pa­ny backed by Colum­bus No­va, and with re­gard to opi­oid law­suits.”

“What he was sell­ing was a line of ac­cess to the Trump ad­min­is­tra­tion,” said Sen. Ron Wyden in an in­ter­view with ABC News. “That would be how I would char­ac­ter­ize it.”

No­var­tis quick­ly kicked back at the Dems’ re­port this morn­ing, say­ing that they had co­op­er­at­ed ful­ly with the probe and that it dis­agreed with its con­clu­sion that the phar­ma gi­ant had of­fered mis­lead­ing com­ments.

This was No­var­tis’ de­fense last May, which the sen­a­tors say doesn’t stand up un­der ex­am­i­na­tion:

“Mr. Co­hen had made no ef­fort to learn any­thing about No­var­tis, or the pol­i­cy is­sues that were of con­cern to No­var­tis specif­i­cal­ly, or the phar­ma­ceu­ti­cal in­dus­try gen­er­al­ly…[he] was not able to pro­vide guid­ance as to how [the Trump ad­min­is­tra­tion] would eval­u­ate and re­spond to the rel­e­vant pol­i­cy is­sues. …[and] was not able to de­liv­er … sub­stan­tive con­sult­ing ad­vice and in­sight.”

Ac­cord­ing to the re­port, No­var­tis’ claim that it sus­pend­ed con­tact af­ter one meet­ing in ear­ly March is sim­ply not true, of­fer­ing re­peat­ed ex­am­ples of e-mail com­mu­ni­ca­tion be­tween Co­hen and Jimenez, as they dis­cussed in­vest­ments, pub­lished ar­ti­cles and pol­i­cy.

(C)on­trary to No­var­tis’s state­ment that it did not have fur­ther en­gage­ment with Mr. Co­hen, the doc­u­ments No­var­tis pro­vid­ed to the Sen­a­tors show that Mr. Co­hen main­tained reg­u­lar con­tact with Mr. Jimenez un­til at least Sep­tem­ber 2017.  No­var­tis’ cur­rent CEO Vas­ant Narasimhan nev­er com­mu­ni­cat­ed with Mr. Co­hen.

The re­port goes on to state that No­var­tis’ claim — made two months ago un­der Narasimhan — that the on­ly rea­son it con­tin­ued to pay Co­hen month­ly pay­ments for a year was that it was con­trac­tu­al­ly ob­lig­at­ed to do so al­so ap­pears to be un­true.

No­var­tis may have mis­led the pub­lic when the com­pa­ny stat­ed that it con­tin­ued to pay Mr. Co­hen the full $1.2 mil­lion even af­ter dis­cov­er­ing that he could not pro­vide the promised con­sult­ing ser­vices be­cause “the con­tract could not be ter­mi­nat­ed at will.” To the ex­tent this as­ser­tion is true, it is be­cause No­var­tis en­gaged in ex­ten­sive ne­go­ti­a­tions that re­sult­ed in weak­er and vaguer con­tract lan­guage than the com­pa­ny had ini­tial­ly sought. But the as­ser­tion does not ap­pear to be cor­rect. It ap­pears that in fact the com­pa­ny could have ter­mi­nat­ed Mr. Co­hen’s con­tract.

The damn­ing re­port al­so notes:

The ini­tial draft con­tract pro­pos­al that No­var­tis sent to Mr. Co­hen – which Mr. Co­hen lat­er mod­i­fied – called ex­plic­it­ly for him to pro­vide “ac­cess to key pol­i­cy­mak­ers” in the Trump ad­min­is­tra­tion, and he rep­re­sent­ed that he would do so. In June 2017, Mr. Jimenez sent Mr. Co­hen an email – “based on our con­ver­sa­tion last week” – trans­mit­ting a six-point plan con­tain­ing No­var­tis’s list of “ideas to low­er drug costs in the U.S.” which, ac­cord­ing to No­var­tis, was for “dis­cus­sion with Trump ad­min­is­tra­tion” of­fi­cials.

The plan in­clud­ed ini­tia­tives cham­pi­oned by the phar­ma­ceu­ti­cal in­dus­try.Mr. Co­hen stat­ed he would show the doc­u­ment to an uniden­ti­fied third par­ty linked to the ad­min­is­tra­tion, who would pro­vide feed­back on the doc­u­ment. Mr. Co­hen promised to pro­vide the third-par­ty feed­back to Mr. Jimenez.

Sev­er­al of the No­var­tis pro­pos­als would lat­er ap­pear in the ad­min­is­tra­tion’s drug pric­ing plan re­leased in May 2018.

An­drew In­trater runs Colum­bus No­va, which is linked to his cousin, Vik­tor Vek­sel­berg, a Russ­ian bil­lion­aire oli­garch with close ties to Russ­ian pres­i­dent Vladimir Putin. Ac­cord­ing to the re­port, Co­hen brought up an in­vest­ment op­por­tu­ni­ty in Yamo Phar­ma­ceu­ti­cals, which has ties to Colum­bus No­va, with Jimenez. States the re­port:

While No­var­tis had de­clined to in­vest in Yamo af­ter a pre­vi­ous meet­ing, Mr. Co­hen asked Mr. Jimenez to “check to see if it was han­dled prop­er­ly.” With­in an hour, Mr. Jimenez promised to over­see the is­sue  per­son­al­ly. Key Colum­bus No­va per­son­nel al­so serve as Yamo of­fi­cials, and Colum­bus  No­va pro­vid­ed “Back Of­fice & Fi­nance Ser­vices” to the phar­ma­ceu­ti­cal com­pa­ny.

The re­port was writ­ten by staff for Sen­a­tors Wyden, Pat­ty Mur­ray, Eliz­a­beth War­ren and Richard Blu­men­thal, who de­mand­ed more in­fo from No­var­tis af­ter the pay­ments were re­vealed in May.

Com­pa­ny ex­ecs knew back in No­vem­ber that they could face a pub­lic out­cry over the is­sue, when Robert Mueller’s team came in to ask ques­tions about the re­la­tion­ship. Co­hen him­self has been at the cen­ter of a me­dia cir­cus sur­round­ing the rev­e­la­tion that he had paid porn star Stormy Daniels $130,000 to keep qui­et about an al­leged af­fair with Trump — writ­ing a check from the same shell com­pa­ny that No­var­tis paid in­to. But No­var­tis nev­er dis­closed any­thing about the fed­er­al in­ves­ti­ga­tion in pub­lic fil­ings.

No­var­tis quick­ly turned de­fen­sive once the pay­ments were re­vealed, trig­ger­ing a fire storm of con­tro­ver­sy. The com­pa­ny quick­ly leaked com­pa­ny mem­os from Narasimhan con­ced­ing that the com­pa­ny had made a mis­take and pledg­ing to do bet­ter in the fu­ture. But the com­pa­ny has nev­er of­fered an ex­pla­na­tion of what the new CEO knew about the Co­hen mat­ter and when he knew it.

No­var­tis quick­ly kicked back at the re­port, not­ing:

We dis­agree with the re­port’s con­clu­sion that we is­sued a mis­lead­ing pub­lic state­ment re­gard­ing the ex­tent of our en­gage­ment with Mr. Co­hen. As the doc­u­ments we pro­duced show, No­var­tis had one and on­ly meet­ing with Mr. Co­hen on March 1, 2017 and then con­clud­ed he was not able to pro­vide the sub­stan­tive con­sult­ing ad­vice and in­sight for which he was hired. We nev­er asked Mr. Co­hen to per­form any ser­vices on our be­half af­ter March 1, nor did he per­form any.

The on­ly ad­di­tion­al com­mu­ni­ca­tion we had be­yond the March 1 meet­ing was when Mr. Co­hen ini­ti­at­ed con­tact with our for­mer CEO, Mr. Jimenez, on a hand­ful of oc­ca­sions. On one of these oc­ca­sions, Mr. Co­hen asked Mr. Jimenez for ideas on how to low­er drug prices. In re­sponse, Mr. Jimenez pro­vid­ed him with a list of well-known ideas for low­er­ing the cost of phar­ma­ceu­ti­cals that had been dis­cussed pub­licly in the in­dus­try.

As we have al­ready ac­knowl­edged, No­var­tis made a mis­take in en­ter­ing in­to the con­tract with Michael Co­hen. And in hind­sight – and cer­tain­ly know­ing every­thing we know now – we should have tried to ter­mi­nate the con­tract with Mr. Co­hen re­gard­less of our views at the time of its le­gal en­force­abil­i­ty.”

Sen­ate De­moc­rats Re­port: White House Ac­cess for Sale by ar­salan arif on Scribd

Im­age: Michael Co­hen. SHUT­TER­STOCK

Regeneron CEO Leonard Schleifer speaks at a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House (AP Photo/Andrew Harnik)

OWS shifts spot­light to drugs to fight Covid-19, hand­ing Re­gen­eron $450M to be­gin large scale man­u­fac­tur­ing in the US

The US government is on a spending spree. And after committing billions to vaccines defense operations are now doling out more of the big bucks through Operation Warp Speed to back a rapid flip of a drug into the market to stop Covid-19 from ravaging patients — possibly inside of 2 months.

The beneficiary this morning is Regeneron, the big biotech engaged in a frenzied race to develop an antibody cocktail called REGN-COV2 that just started a late-stage program to prove its worth in fighting the virus. BARDA and the Department of Defense are awarding Regeneron a $450 million contract to cover bulk delivery of the cocktail starting as early as late summer, with money added for fill/finish and storage activities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Donald and Melania Trump watch the smoke of fireworks from the South Lawn of the White House on July 4, 2020 (via Getty)

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack

We are unleashing our nation’s scientific brilliance and will likely have a therapeutic and/or vaccine solution long before the end of the year.

— Donald Trump, July 4

Next week administration officials plan to promote a new study they say shows promising results on therapeutics, the officials said. They wouldn’t describe the study in any further detail because, they said, its disclosure would be “market-moving.”

— NBC News, July 3

Something’s cooking. And it’s not just July 4 leftovers involving stale buns and uneaten hot dogs.

Over the long weekend observers picked up signs that the focus in the Trump administration may swiftly shift from the bright spotlight on vaccines being promised this fall, around the time of the election, to include drugs that could possibly keep patients out of the hospital and take the political sting out of the soaring Covid-19 numbers causing embarrassment in states that swiftly reopened — as Trump cheered along.

So far, Gilead has been the chief beneficiary of the drive on drugs, swiftly offering enough early data to get remdesivir an emergency authorization and into the hands of the US government. But their drug, while helpful in cutting stays, is known for a limited, modest effect. And that won’t tamp down on the hurricane of criticism that’s been tearing at the White House, and buffeting the president’s most stalwart core defenders as the economy suffers.

We’ve had positive early-stage vaccine data, most recently from Pfizer and BioNTech, playing catchup on an mRNA race led by Moderna — where every little sign of potential trouble is magnified into a lethal threat, just as every advance excites a frenzy of support. But that race still has months to play out, with more Phase I data due ahead of the mid-stage numbers looming ahead. A vaccine may not be available in large enough quantities until well into 2021, which is still wildly ambitious.

So what about a drug solution?

Trump’s initial support for a panacea focused on hydroxychloroquine. But that fizzled in the face of data underscoring its ineffectiveness — killing trials that aren’t likely to be restarted because of a recent population-based study offering some support. And there are a number of existing drugs being repurposed to see how they help hospitalized patients.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Shoshanna Shendelman, Applied Therapeutics CEO (Applied Therapeutics)

A lit­tle biotech slaps back at a 'crim­i­nal' short at­tack, vow­ing to pur­sue a pros­e­cu­tion of their case

As short attacks go, Biotech Research Partners’ assault on Applied Therapeutics’ “cherry picked” data and a variety of so-called red flags didn’t cause a whole lot of damage. Ahead of the July 4 holiday, its shares $APLT were dinged and showed signs of quick recovery.

But that didn’t stop an incendiary response, as the biotech swung into action bright and early Monday morning.

Applied Therapeutics accused the authors of the short report of manipulating graphs and figures, misrepresenting data and included factual misrepresentations — all of which added up, in their view, to fraud.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Noubar Afeyan, Flagship CEO and Tessera chairman (Victor Boyko/Getty Images)

Flag­ship ex­ecs take a les­son from na­ture to mas­ter ‘gene writ­ing,’ launch­ing a star-stud­ded biotech with big am­bi­tions to cure dis­ease

Flagship Pioneering has opened up its deep pockets to fund a biotech upstart out to revolutionize the whole gene therapy/gene editing field — before gene editing has even made it to the market. And they’ve surrounded themselves with some marquee scientists and execs who have crowded around to help shepherd the technology ahead.

The lead player here is Flagship general partner Geoff von Maltzahn, an MIT-trained synthetic biologist who set out in 2018 to do CRISPR — a widely used gene editing tool — and other rival technologies one or two better. Von Maltzahn has been working with Sana co-founder Jake Rubens, another synthetic biology player out of MIT who he describes as his “superstar,” who’s taken the CSO role.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Squab­bles with gov­ern­ment de­lay Mod­er­na’s PhI­II — re­ports; No­vavax se­cures largest Warp Speed deal yet: $1.6B

A much-anticipated Phase III trial for Moderna’s Covid-19 vaccine is being held up as the company delayed submitting trial protocols and sparred with government scientists on how to run the study and even what the benchmark for success should be, Reuters reported.

Moderna, the first US company to put their vaccine into human testing, was supposed to enter a 30,000-person study this month in partnership with the NIH to determine whether it can prevent infection. STAT reported last week that the trial was facing delays over the protocol, but that a July start was still possible. Neither the NIH nor Moderna ever disclosed a specific date the trial should start, but Reuters reported that the agency had hoped to begin on July 10.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Cel­lec­tis slammed af­ter pa­tient dies and FDA slaps a hold on their tri­al for an off-the-shelf CAR-T for mul­ti­ple myelo­ma

Cellectis was slammed after the market close on Monday as the biotech reported that the FDA demanded it hit the brakes on their MELANI-01 trial for their off-the-shelf cell therapy UCARTCS1A after one of the patients in the study died of treatment-related cardiac arrest.

The multiple myeloma patient had previously been treated unsuccessfully with various therapies, noted the biotech, and had been given dose level two (DL2) of their allogeneic CAR-T.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Im­munomedics spells out PFS ben­e­fit of Trodelvy in mTNBC, hunt­ing a full OK just weeks af­ter ac­cel­er­at­ed ap­proval

By the time the FDA finally granted an accelerated OK for Immunomedics’ Trodelvy, we already got a very strong hint that their confirmatory Phase III study in metastatic triple-negative breast cancer was a success.

That’s because the independent data safety monitoring committee recommended that the trial be stopped early. But just what pointed them to the conclusion was still unclear.

“We do not know the totality of their decision other than it’s pretty evident that the primary endpoint was met; otherwise they could not request to halt the study,” Behzad Aghazadeh, the executive chairman, told Endpoints News at the time.

Bill Haney, Dragonfly CEO (Dave Pedley/Getty Images for SXSW)

A boom­ing Drag­on­fly is tak­ing its TriN­KETs to Copen­hagen as the lat­est Bris­tol My­ers pact spurs ex­pan­sion plans — out­side the US

Bristol Myers Squibb is making a habit out of collaborating with the crew at Dragonfly, adding their 3rd deal in a series that now will take them into newly charted R&D territory. And the fast-growing team at the Cambridge-based biotech is adding a facility in Copenhagen for its next growth spurt, where the government is making it easy to recruit scientists internationally as the U.S. throttles back.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Teamed up with NIH, Re­gen­eron launch­es PhI­II pre­ven­tion tri­al for an­ti­body cock­tail

As Regeneron moves its antibody cocktail into Phase II/III trials testing REGN-COV2 as a treatment for both hospitalized and non-hospitalized patients with Covid-19, the biotech is also starting a Phase III in the prevention setting.

The National Institute of Allergy and Infectious Diseases — which orchestrated the large, randomized study for remdesivir that produced positive results — will jointly run the study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.